Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Recipient : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2010
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Recipient : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
